This analysis found several risk factors to predict relapse in Graves' disease, which can be combined in a risk score. Prospective studies should evaluate the prognostic accuracy of such a score to guide treatment decisions.

Current evidence suggests a possible relevant reduction in relapse risk when immunosuppressive drugs are added to standard treatment of Graves' disease. The small number of trials with high heterogeneity in regard to treatment modalities and the lack of systematic reporting of adverse effects calls for larger, conclusive trials.

No abstract

No abstract

No abstract